Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials
暂无分享,去创建一个
S. Vermeire | S. Hanauer | Qian Zhou | W. Sandborn | W. Reinisch | J. Colombel | J. Petersson | A. Lazar | K. Kligys
[1] Yuhong Yuan,et al. Patient‐Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta‐analysis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[2] B. Feagan,et al. Rapid Response to Vedolizumab Therapy in Biologic‐Naive Patients With Inflammatory Bowel Diseases , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] C. Langner,et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. , 2017, Journal of Crohn's & colitis.
[4] S. Vermeire,et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis , 2017, The New England journal of medicine.
[5] C. O'Morain,et al. European Crohn’s and Colitis Organisation Topical Review on Environmental Factors in IBD , 2016, Journal of Crohn's & colitis.
[6] T. Murdoch,et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target , 2015, The American Journal of Gastroenterology.
[7] M. Silverberg,et al. Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis , 2015, Inflammatory bowel diseases.
[8] M. Skup,et al. Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3 , 2014, The American Journal of Gastroenterology.
[9] I. Koutroubakis,et al. Multipotent role of platelets in inflammatory bowel diseases: a clinical approach. , 2014, World journal of gastroenterology.
[10] G. Petris,et al. European consensus on the histopathology of inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.
[11] A. Yazıcı,et al. Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis , 2013, Rheumatology International.
[12] G. D'Haens,et al. One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2 , 2013, Alimentary pharmacology & therapeutics.
[13] S. Vermeire,et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .
[14] G. D'Haens,et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.
[15] S. Schreiber,et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial , 2011, Gut.
[16] G. Corazza,et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-α treatment , 2010, Haematologica.
[17] J. Gisbert,et al. Anemia and inflammatory bowel diseases. , 2009, World journal of gastroenterology.
[18] K. Van Steen,et al. Long-term outcome after infliximab for refractory ulcerative colitis. , 2008, Journal of Crohn's & colitis.
[19] E. Levitan,et al. Meta-Analysis of the Placebo Response in Ulcerative Colitis , 2008, Digestive Diseases and Sciences.
[20] P. Rutgeerts,et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis , 2007, Inflammatory bowel diseases.
[21] W. Sandborn,et al. Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.
[22] Paul Rutgeerts,et al. Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.
[23] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .
[24] M. Feldmann,et al. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. , 1997, British journal of rheumatology.
[25] J. Larson. The MOS 36-Item Short form Health Survey , 1997, Evaluation & the health professions.
[26] C. Sherbourne,et al. The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .
[27] G. Guyatt,et al. A new measure of health status for clinical trials in inflammatory bowel disease. , 1989, Gastroenterology.
[28] T. Molnár,et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. , 2017, Journal of Crohn's & colitis.
[29] M. Skup,et al. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. , 2014, Gastroenterology.
[30] Ware J.E.Jr.,et al. THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .